Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: A temporal analysis of CD34+ absolute counts and subsets

I. H. Chin-Yee, M. Keeney, Alexander Keith Stewart, A. Belch, I. Bence-Buckler, S. Couban, K. Howson-Jan, M. Rubinger, D. Stewart, R. Sutherland, V. Paragamian, M. Bhatia, R. Foley

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Patients (n = 69) with multiple myeloma undergoing peripheral blood stem cell collection (PBSC) were treated with cyclophosphamide and a combination of recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim) and recombinant methionyl human stem cell factor (r-metHuSCF, ancestim). The objectives of this study were to determine: (1) The proportion of patients reaching a target yield of ≥5 × 106 CD34+ cells/kg in one or two successive large-volume (20 liter) leukapheresis procedures; (2) the optimal collection time for leukapheresis; (3) mobilization kinetics of CD34+ subsets in response to GCSF/SCF. All patients were mobilized with cyclophosphamide (2.5 g/m2) on day 0 followed by filgrastim (10 μg/kg ) plus ancestim (20 μg/kg) commencing day 1 and continuing to day 11 or 12. Of the 65 evaluable patients, 57 were considered not heavily pretreated and 96.5% obtained a target of ≥5 × 106/kg in one collection. The median CD34+ cells/kg was 39.5 × 106 (range: 5.2-221.2 × 106). Subset analysis demonstrated the number of CD38-, CD33-, and CD133+ peaked at day 11; and CD34+, CD90+ cells peaked at day 10. The optimum day for leukapheresis was determined to be day 11. The median absolute peripheral blood CD34+ cell numbers on day 11 was 665 × 106/l (range: 76-1481 × 106/l). Eight of the 10 heavily pretreated patients were evaluable: three achieved the target dose in one leukapheresis (37.5%) and three (37.5%) achieved the target dose with two leukaphereses. Use of this mobilization strategy allowed the collection of high numbers of CD34+ cells and early progenitors and the ability to predictably schedule leukapheresis.

Original languageEnglish (US)
Pages (from-to)851-860
Number of pages10
JournalBone Marrow Transplantation
Volume30
Issue number12
DOIs
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Leukapheresis
Multiple Myeloma
Cyclophosphamide
Blood Cell Count
Filgrastim
ancestim
Appointments and Schedules
Stem Cells
Cell Count

Keywords

  • CD34 subsets
  • G-CSF
  • Multiple myeloma
  • SCF
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma : A temporal analysis of CD34+ absolute counts and subsets. / Chin-Yee, I. H.; Keeney, M.; Stewart, Alexander Keith; Belch, A.; Bence-Buckler, I.; Couban, S.; Howson-Jan, K.; Rubinger, M.; Stewart, D.; Sutherland, R.; Paragamian, V.; Bhatia, M.; Foley, R.

In: Bone Marrow Transplantation, Vol. 30, No. 12, 12.2002, p. 851-860.

Research output: Contribution to journalArticle

Chin-Yee, IH, Keeney, M, Stewart, AK, Belch, A, Bence-Buckler, I, Couban, S, Howson-Jan, K, Rubinger, M, Stewart, D, Sutherland, R, Paragamian, V, Bhatia, M & Foley, R 2002, 'Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: A temporal analysis of CD34+ absolute counts and subsets', Bone Marrow Transplantation, vol. 30, no. 12, pp. 851-860. https://doi.org/10.1038/sj.bmt.1703765
Chin-Yee, I. H. ; Keeney, M. ; Stewart, Alexander Keith ; Belch, A. ; Bence-Buckler, I. ; Couban, S. ; Howson-Jan, K. ; Rubinger, M. ; Stewart, D. ; Sutherland, R. ; Paragamian, V. ; Bhatia, M. ; Foley, R. / Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma : A temporal analysis of CD34+ absolute counts and subsets. In: Bone Marrow Transplantation. 2002 ; Vol. 30, No. 12. pp. 851-860.
@article{d658db4631a34e0f8e3747a0f38e7b35,
title = "Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: A temporal analysis of CD34+ absolute counts and subsets",
abstract = "Patients (n = 69) with multiple myeloma undergoing peripheral blood stem cell collection (PBSC) were treated with cyclophosphamide and a combination of recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim) and recombinant methionyl human stem cell factor (r-metHuSCF, ancestim). The objectives of this study were to determine: (1) The proportion of patients reaching a target yield of ≥5 × 106 CD34+ cells/kg in one or two successive large-volume (20 liter) leukapheresis procedures; (2) the optimal collection time for leukapheresis; (3) mobilization kinetics of CD34+ subsets in response to GCSF/SCF. All patients were mobilized with cyclophosphamide (2.5 g/m2) on day 0 followed by filgrastim (10 μg/kg ) plus ancestim (20 μg/kg) commencing day 1 and continuing to day 11 or 12. Of the 65 evaluable patients, 57 were considered not heavily pretreated and 96.5{\%} obtained a target of ≥5 × 106/kg in one collection. The median CD34+ cells/kg was 39.5 × 106 (range: 5.2-221.2 × 106). Subset analysis demonstrated the number of CD38-, CD33-, and CD133+ peaked at day 11; and CD34+, CD90+ cells peaked at day 10. The optimum day for leukapheresis was determined to be day 11. The median absolute peripheral blood CD34+ cell numbers on day 11 was 665 × 106/l (range: 76-1481 × 106/l). Eight of the 10 heavily pretreated patients were evaluable: three achieved the target dose in one leukapheresis (37.5{\%}) and three (37.5{\%}) achieved the target dose with two leukaphereses. Use of this mobilization strategy allowed the collection of high numbers of CD34+ cells and early progenitors and the ability to predictably schedule leukapheresis.",
keywords = "CD34 subsets, G-CSF, Multiple myeloma, SCF, Stem cell mobilization",
author = "Chin-Yee, {I. H.} and M. Keeney and Stewart, {Alexander Keith} and A. Belch and I. Bence-Buckler and S. Couban and K. Howson-Jan and M. Rubinger and D. Stewart and R. Sutherland and V. Paragamian and M. Bhatia and R. Foley",
year = "2002",
month = "12",
doi = "10.1038/sj.bmt.1703765",
language = "English (US)",
volume = "30",
pages = "851--860",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma

T2 - A temporal analysis of CD34+ absolute counts and subsets

AU - Chin-Yee, I. H.

AU - Keeney, M.

AU - Stewart, Alexander Keith

AU - Belch, A.

AU - Bence-Buckler, I.

AU - Couban, S.

AU - Howson-Jan, K.

AU - Rubinger, M.

AU - Stewart, D.

AU - Sutherland, R.

AU - Paragamian, V.

AU - Bhatia, M.

AU - Foley, R.

PY - 2002/12

Y1 - 2002/12

N2 - Patients (n = 69) with multiple myeloma undergoing peripheral blood stem cell collection (PBSC) were treated with cyclophosphamide and a combination of recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim) and recombinant methionyl human stem cell factor (r-metHuSCF, ancestim). The objectives of this study were to determine: (1) The proportion of patients reaching a target yield of ≥5 × 106 CD34+ cells/kg in one or two successive large-volume (20 liter) leukapheresis procedures; (2) the optimal collection time for leukapheresis; (3) mobilization kinetics of CD34+ subsets in response to GCSF/SCF. All patients were mobilized with cyclophosphamide (2.5 g/m2) on day 0 followed by filgrastim (10 μg/kg ) plus ancestim (20 μg/kg) commencing day 1 and continuing to day 11 or 12. Of the 65 evaluable patients, 57 were considered not heavily pretreated and 96.5% obtained a target of ≥5 × 106/kg in one collection. The median CD34+ cells/kg was 39.5 × 106 (range: 5.2-221.2 × 106). Subset analysis demonstrated the number of CD38-, CD33-, and CD133+ peaked at day 11; and CD34+, CD90+ cells peaked at day 10. The optimum day for leukapheresis was determined to be day 11. The median absolute peripheral blood CD34+ cell numbers on day 11 was 665 × 106/l (range: 76-1481 × 106/l). Eight of the 10 heavily pretreated patients were evaluable: three achieved the target dose in one leukapheresis (37.5%) and three (37.5%) achieved the target dose with two leukaphereses. Use of this mobilization strategy allowed the collection of high numbers of CD34+ cells and early progenitors and the ability to predictably schedule leukapheresis.

AB - Patients (n = 69) with multiple myeloma undergoing peripheral blood stem cell collection (PBSC) were treated with cyclophosphamide and a combination of recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim) and recombinant methionyl human stem cell factor (r-metHuSCF, ancestim). The objectives of this study were to determine: (1) The proportion of patients reaching a target yield of ≥5 × 106 CD34+ cells/kg in one or two successive large-volume (20 liter) leukapheresis procedures; (2) the optimal collection time for leukapheresis; (3) mobilization kinetics of CD34+ subsets in response to GCSF/SCF. All patients were mobilized with cyclophosphamide (2.5 g/m2) on day 0 followed by filgrastim (10 μg/kg ) plus ancestim (20 μg/kg) commencing day 1 and continuing to day 11 or 12. Of the 65 evaluable patients, 57 were considered not heavily pretreated and 96.5% obtained a target of ≥5 × 106/kg in one collection. The median CD34+ cells/kg was 39.5 × 106 (range: 5.2-221.2 × 106). Subset analysis demonstrated the number of CD38-, CD33-, and CD133+ peaked at day 11; and CD34+, CD90+ cells peaked at day 10. The optimum day for leukapheresis was determined to be day 11. The median absolute peripheral blood CD34+ cell numbers on day 11 was 665 × 106/l (range: 76-1481 × 106/l). Eight of the 10 heavily pretreated patients were evaluable: three achieved the target dose in one leukapheresis (37.5%) and three (37.5%) achieved the target dose with two leukaphereses. Use of this mobilization strategy allowed the collection of high numbers of CD34+ cells and early progenitors and the ability to predictably schedule leukapheresis.

KW - CD34 subsets

KW - G-CSF

KW - Multiple myeloma

KW - SCF

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=0036952592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036952592&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703765

DO - 10.1038/sj.bmt.1703765

M3 - Article

C2 - 12476276

AN - SCOPUS:0036952592

VL - 30

SP - 851

EP - 860

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -